# Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

> **NCT05765825** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan University** · enrollment: 61 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** serplulimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **RADIATION:** Thoracic radiation therapy (TRT)

## Key facts

- **NCT ID:** NCT05765825
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2024-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765825, "Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05765825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*